Although, PSA has replaced prostatic acid phosphatase (PAP) as a marker long back but due to a few shortcomings including severe inaccuracy for advanced-stage disease [9] certain new and advanced biomarkers, such as Select MDx (high accuracy for high-grade PCa), PHI, 4K, ExoDx, Mi-prostate score, PROGENSA PCA-3, prostate-specific membrane antigen, and survivin have been developed to diagnose prostate cancer precisely [10]. This evidence concerns the gene ACP3 and Familial prostate cancer.